Clarity Pharmaceuticals Ltd (CU6.AX)

AUD 1.9

(13.1%)

Market Cap (In AUD)

610.56 Million

Revenue (In AUD)

11.5 Million

Net Income (In AUD)

-42.32 Million

Avg. Volume

2.2 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.69-8.975
PE
-11.87
EPS
-0.16
Beta Value
1.678
ISIN
AU0000165375
CUSIP
-
CIK
-
Shares
321352000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Colin David Biggin Ph.D.
Employee Count
-
Website
https://www.claritypharmaceuticals.com
Ipo Date
2021-08-25
Details
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.